In one paragraphArticle in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Dorottya LaczkoDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
Patricia TsaoCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
Ruth-Anne PaiCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0001-9413-7611 Joseph ZinskiCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0002-5120-5386 Michael V GonzalezCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
Melanie D MumauCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0003-2145-8347 Tobias RaabeDivision of Translational Medicine and Human Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0001-8944-3278 Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0003-1544-1493 Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Taku KambayashiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
David C FajgenbaumCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0002-7367-8184 Funding
mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1MNHLBI NIH HHS R01 HL141408
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID40811789
PMCPMC12767808
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390